## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6009881

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
LIFESCI PHARMACEUTICALS, INC.	02/21/2020

### **RECEIVING PARTY DATA**

Name:	ATTUNE PHARMACEUTICALS, INC.		
Street Address:	t Address: 250 W. 55TH STREET		
Internal Address:	34TH FLOOR		
City:	NEW YORK		
State/Country:	NEW YORK		
Postal Code:	10019		

## **PROPERTY NUMBERS Total: 4**

Property Type	Number		
Application Number:	62187786		
Application Number:	62190223		
Patent Number:	10023557		
Patent Number:	10308637		

### CORRESPONDENCE DATA

**Fax Number:** (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** (650) 493-9300

Email:patentdocket@wsgr.com, randico@wsgr.comCorrespondent Name:WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	48367-711/101/102/201/301	
NAME OF SUBMITTER:	ROSE ANDICO	
SIGNATURE:	/Rose Andico/	
DATE SIGNED:	03/11/2020	

**Total Attachments: 2** 

source=48367-711 Patent Family - Executed Corporate Assignment from LSP to Attune#page1.tif

PATENT REEL: 052090 FRAME: 0271

505963174

source=48367-711 Patent Family - Executed Corporate Assignment from LSP to Attune#page2.tif

PATENT REEL: 052090 FRAME: 0272

#### CORPORATE TO CORPORATE ASSIGNMENT

Docket Number: 48367-711 Patent Family (see Appendix A attached)

WHEREAS, <u>LifeSci Pharmaceuticals</u>, <u>Inc.</u> (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Application(s) listed in <u>Appendix A</u> attached hereto, and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions").

WHEREAS, <u>Attune Pharmaceuticals</u>, <u>Inc.</u>, a corporation incorporated under the laws of the <u>State of Delaware</u>, having a place of business at <u>250 W. 55<sup>th</sup> Street</u>, <u>34<sup>th</sup> Floor</u>, <u>New York</u>, <u>New York 10019</u>, <u>US</u>, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Inventions, and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

- 1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).
- 2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.
- 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives. and shall be binding upon the Assignor, its successors, assigns and other legal representatives.
- 4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

ASSIGNOR:  Date: 7-21-2020	By:  Name: Andrew McDonald Title: Chief Executive Officer
RECEIVED AND AGREED TO BY ASSIGNEE:	ATTUNE PHARMACEUTICALS, INC.
Date: 2-2(-2020)	By: Name: Andrew McDonald
	Title: Chief Executive Officer

# APPENDIX A

Attorney	Docket No.	Country	Application No.	Filing Date	Patent No.	Issue Date	Application Title
48367-71	1 602	wo	PCT/IB2016/001048	06/30/2016			THERAPEUTIC INHIBITORY COMPOUNDS
48367-71	1 101	US	62/187,786	07/01/2015			THERAPEUTIC INHIBITORY COMPOUNDS
48367-71	1 102	US	62/190,223	07/08/2015			THERAPEUTIC INHIBITORY COMPOUNDS
48367-71	1 201	US	15/199,785	06/30/2016	10,023,557	07/17/2018	THERAPEUTIC INHIBITORY COMPOUNDS
48367-71	1 611	EP	16817315.1	06/30/2016			THERAPEUTIC INHIBITORY COMPOUNDS
48367-71	1 301	US	16/009,093	06/14/2018	10,308,637	06/04/2019	THERAPEUTIC INHIBITORY COMPOUNDS

Page 2 of 2 PATENT
D20 REEL: 052090 FRAME: 0274

RECORDED: 03/11/2020